Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (51-60 of 159) with videos related to

Pageof 16
Sort By:
Annals of the Rheumatic Diseases|August 28, 2013
The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritisJanet E Pope, Boulos Haraoui, J Carter Thorne, et al.
The Journal of Rheumatology|January 3, 2015
Arthritis clinical trials at a crossroadJanet E Pope, J Carter Thorne, Boulos P Haraoui, et al.
Clinical Proteomics|June 5, 2019
Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometryShalini M Mahendran, Edward C Keystone, Roman J Krawetz, et al.
The Lancet. Infectious Diseases|March 5, 2003
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementMichael A Gardam, Edward C Keystone, Richard Menzies, et al.
The Journal of Rheumatology|October 7, 2004
Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion numberMichael J Wasserman, Deborah A Weber, Judith A Guthrie, et al.
The Journal of Rheumatology|July 3, 2013
Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritisEdward C Keystone, Désirée van der Heijde, Arthur Kavanaugh, et al.
Clinical and Experimental Rheumatology|November 19, 2013
Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experienceGrant W Cannon, Brian C Wang, Grace S Park, et al.
Rheumatology (Oxford, England)|October 28, 2009
Fibrocyte activation in rheumatoid arthritisCarole L Galligan, Katherine A Siminovitch, Edward C Keystone, et al.
BMJ Open|March 6, 2023
Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in CanadaMohammad Movahedi, Denis Choquette, Louis Coupal, et al.
Arthritis and Rheumatism|February 12, 2004
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trialEdward C Keystone, Michael H Schiff, Joel M Kremer, et al.
Pageof 16

Showing results (51-60 of 159) with videos related to

Sort By:
Pageof 16
Annals of the Rheumatic Diseases|August 28, 2013
The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritisJanet E Pope, Boulos Haraoui, J Carter Thorne, et al.
The Journal of Rheumatology|January 3, 2015
Arthritis clinical trials at a crossroadJanet E Pope, J Carter Thorne, Boulos P Haraoui, et al.
Clinical Proteomics|June 5, 2019
Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometryShalini M Mahendran, Edward C Keystone, Roman J Krawetz, et al.
The Lancet. Infectious Diseases|March 5, 2003
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementMichael A Gardam, Edward C Keystone, Richard Menzies, et al.
The Journal of Rheumatology|October 7, 2004
Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion numberMichael J Wasserman, Deborah A Weber, Judith A Guthrie, et al.
The Journal of Rheumatology|July 3, 2013
Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritisEdward C Keystone, Désirée van der Heijde, Arthur Kavanaugh, et al.
Clinical and Experimental Rheumatology|November 19, 2013
Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experienceGrant W Cannon, Brian C Wang, Grace S Park, et al.
Rheumatology (Oxford, England)|October 28, 2009
Fibrocyte activation in rheumatoid arthritisCarole L Galligan, Katherine A Siminovitch, Edward C Keystone, et al.
BMJ Open|March 6, 2023
Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in CanadaMohammad Movahedi, Denis Choquette, Louis Coupal, et al.
Arthritis and Rheumatism|February 12, 2004
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trialEdward C Keystone, Michael H Schiff, Joel M Kremer, et al.
Pageof 16